Table 1 Patients clinical characteristics
Parameter | Â | Overall | Oral rinse-derived ctDNA detectable | Plasma ctDNA detectable |
|---|---|---|---|---|
Number |  | N = 123 | N = 116 | N = 99 |
Gender | Female | 58 (47.2%) | 56 (48.3%) | 49 (49.5%) |
Male | 65 (52.8%) | 60 (51.7%) | 50 50.5%) | |
Smoking status | Never or former | 107 (87.0%) | 102 (87.9%) | 88 (88.9%) |
Current | 16 (13.0%) | 14 (12.1%) | 11 (11.1%) | |
Alcohol status | Never or former | 106 (86.2%) | 101 (87.1%) | 86 (86.9%) |
Current | 17 (13.8%) | 15 (12.9%) | 13 (13.1%) | |
Age | <60 | 64 (52.0%) | 59 (50.9%) | 54 (54.5%) |
≥60 | 59 (48.0%) | 57 (49.1%) | 45 (45.5%) | |
Primary tumour site | Tongue | 41 (33.3%) | 37 (31.9%) | 33 (33.3%) |
Buccal | 35 (28.5%) | 34 (29.3%) | 31 (31.3%) | |
Gingiva | 25 (20.3%) | 25 (21.6%) | 18 (18.2%) | |
Others | 22 (17.9%) | 20 (17.2%) | 17 (17.2%) | |
Differentiation* | Grade I | 84 (68.3%) | 78 (67.2%) | 63 (63.6%) |
Grade II/III | 39 (31.7%) | 38 (32.8%) | 36 (36.4%) | |
T stage | T1/T2 | 83 (67.5%) | 78 (67.2%) | 63 (63.6%) |
T3/T4 | 40 (32.5%) | 38 (32.8%) | 36 (36.4%) | |
Lymph node metastasis* | N0 | 85 (69.1%) | 79 (68.1%) | 63 (63.6%) |
N1-N3 | 38 (30.9%) | 37 (31.9%) | 36 (36.4%) | |
Metastatic disease | M0 | 119 (96.7%) | 112 (96.6%) | 96 (97.0%) |
M1 | 4 (3.3%) | 4 (3.4%) | 3 (3.0%) | |
Clinical stage* | Stage I/II | 68 (55.3%) | 63 (54.3%) | 48 (48.5%) |
Stage III/IV | 55 (44.7%) | 53 (45.7%) | 51 (51.5%) | |
1-year disease status* | Recurrence | 64 (52.0%) | 59 (50.9%) | 46 (46.5%) |
Non-recurrence | 59 (48.0%) | 57 (49.1%) | 53 (53.5%) | |
Treatment modality | Surgery only | 13 (10.6%) | 12 (10.3%) | 11 (11.1%) |
Surgery + radiation or chemoradiation | 24 (19.5%) | 22 (19.0%) | 18 (18.2%) | |
Surgery + systemic therapy | 86 (69.9%) | 82 (70.7%) | 70 (70.7%) |
